Gefitinib does not increase survival in lung cancer patients.
Golsteyn
Roy M
RM
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D002986:Clinical Trials as Topic; D017277:Drug Approval; D000077156:Gefitinib; D005838:Genotype; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D011799:Quinazolines / Q000627:therapeutic use*; D017211:Treatment Failure; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib